| Phyllis E Shelton, MD | |
|
509 Biltmore Ave, Asheville, NC 28801-4601 | |
| (843) 237-3378 | |
| (843) 237-5073 |
| Full Name | Phyllis E Shelton |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 41 Years |
| Location | 509 Biltmore Ave, Asheville, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679535348 | NPI | - | NPPES |
| 930088962 | Other | NC | RAILROAD |
| 8912551 | Medicaid | NC | |
| 12551 | Other | NC | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 200000134 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
| The Mcdowell Hospital | Marion, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Coverage Corp | 3072412592 | 364 |
News Archive
The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.
A new nanoparticle-based drug can boost the body's innate immune system and make it more effective at fighting off tumors, researchers at UT Southwestern have shown.
The risk of mortality, and of developing a number of cancers, is lowest in light drinkers consuming an average of less than one drink per day across their lifetime, and the risk of some cancers increases with each additional drink per week, according to a new study, published this week in PLOS Medicine by Andrew Kunzmann of Queen's University Belfast, and colleagues.
Dr. Reddy's Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2010 was filed with the United States Securities and Exchange Commission.
Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.
› Verified 3 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20100202000365 |
News Archive
The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.
A new nanoparticle-based drug can boost the body's innate immune system and make it more effective at fighting off tumors, researchers at UT Southwestern have shown.
The risk of mortality, and of developing a number of cancers, is lowest in light drinkers consuming an average of less than one drink per day across their lifetime, and the risk of some cancers increases with each additional drink per week, according to a new study, published this week in PLOS Medicine by Andrew Kunzmann of Queen's University Belfast, and colleagues.
Dr. Reddy's Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2010 was filed with the United States Securities and Exchange Commission.
Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Phyllis E Shelton, MD Po Box 1856, Pawleys Island, SC 29585-1856 Ph: (843) 237-3378 | Phyllis E Shelton, MD 509 Biltmore Ave, Asheville, NC 28801-4601 Ph: (843) 237-3378 |
News Archive
The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.
A new nanoparticle-based drug can boost the body's innate immune system and make it more effective at fighting off tumors, researchers at UT Southwestern have shown.
The risk of mortality, and of developing a number of cancers, is lowest in light drinkers consuming an average of less than one drink per day across their lifetime, and the risk of some cancers increases with each additional drink per week, according to a new study, published this week in PLOS Medicine by Andrew Kunzmann of Queen's University Belfast, and colleagues.
Dr. Reddy's Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2010 was filed with the United States Securities and Exchange Commission.
Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.
› Verified 3 days ago
Vanessa C Peluso, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1100 Tunnel Rd, Asheville, NC 28805 Phone: 828-298-7911 | |
Dr. Elizabeth T Mccarty, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 Patton Ave, Asheville, NC 28806 Phone: 828-620-0876 | |
Terrence W Burt, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 843-237-3378 Fax: 843-237-5073 | |
Cody Russell, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Dominic Fredrick Tutera, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-257-4472 | |
Krystin Thomas, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Christopher Foster, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1948 Fax: 828-213-1950 |